Cincinnati, OH2 Active Studies

Polycystic Kidney Disease Clinical Trials in Cincinnati, OH

Find 2 actively recruiting polycystic kidney disease clinical trials in Cincinnati, OH. Connect with local research sites and explore new treatment options.

2
Active Trials
1
Sponsors
40
Enrolling

Recruiting Polycystic Kidney Disease Studies in Cincinnati

About Polycystic Kidney Disease Clinical Trials in Cincinnati

Polycystic kidney disease (PKD) is a genetic disorder causing numerous fluid-filled cysts to grow in the kidneys, leading to kidney enlargement and progressive loss of function. Autosomal dominant PKD is the most common form. Treatment includes tolvaptan and management of complications.

There are currently 2 polycystic kidney disease clinical trials recruiting participants in Cincinnati, OH. These studies are seeking a combined 40 participants. Research is being sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Polycystic Kidney Disease Clinical Trials in Cincinnati — FAQ

Are there polycystic kidney disease clinical trials in Cincinnati?

Yes, there are 2 polycystic kidney disease clinical trials currently recruiting in Cincinnati, OH. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Cincinnati?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Cincinnati research site will contact you about next steps.

Are clinical trials in Cincinnati free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Cincinnati studies also compensate for your time and travel.

What polycystic kidney disease treatments are being tested?

The 2 active trials in Cincinnati are testing new therapies including novel drugs, biologics, and treatment approaches for polycystic kidney disease.

Data updated March 2, 2026 from ClinicalTrials.gov